



SUNDAY 28 June 2026

Breakfast from 7.30am - Foyer E 8am start			
0830-1030	The Perfect Pitch Hall C Co-Chairs: Andrisha Inderjeeth & Mike Cilento - Consumer experience - Will McDonald - Integrating translational research into your clinical trial – Tahlia Scheinberg - Having 360° Insight: Designing a meaningful trial for your career stage - Ben Tran - Quality of life outcomes, psychosocial outcomes, PROMs and PREMs (trial design for meaningful results) – Haryana Dhillon - Funding and personal experience - Paul Flynn Q&A	0800 – 1030 Clinical Trial Coordinators Session Riverbank 2&3 Co-Chairs: Monika Tencic & Brandon Holt - From Bedside to Bench and Back: Why Translational Research Begins at the Trial Site – Ed Kwan - What matters most to a Genetic Counsellor? – Vanessa Huntley - Delivering Theranostics: Workflow, Patients and Practice – Karen Lindsay - From Site to Sponsor: Strengthening Clinical Trial Operations Through Site Experience – Meghan Baronet - Mental health self-care: spotlight on burnout and impostor syndrome - Gareth Furber Survey Q&A	0800 – 1030 ANZUP PCFA Nurses & Allied Health Symposium E2&E3  Sponsored by: Co-Chairs: Mel Caruso and Ally Morrice PhD updates: Helen Anderson Kath Schubach Sally Sara Russell Briggs Nurse-led projects: - SA Prostate Cancer Clinical Outcomes Collaborative – A nurse’s perspective - Sophie Otto - QI Project - From Biopsy to Results - Kerry Santoro - QI Project - Bridging the Gap - Enhanced communication and knowledge sharing - Eva Gauci - QI Project - Creation of an online platform for a survivorship care plan - Levina Saad - Leading research as a Nurse Chief Investigator - Cynthia Hawkes - Sharing nurse led research or project findings at conferences - Nicole Heneka - GU Cancer Survivorship - Catherine Paterson

1030-1100	Morning tea - Foyer E	
1100-1230	Translational Highlights Session Hall C Co-Chairs: Renea Taylor and Luke Selth - Tissue Architecture and Spatial Niches Predict Prognosis in the Prostate Cancer Microenvironment - Marianna Kruithof-de Julio - Unravelling mechanisms and identifying therapies to relieve BCG induced bladder side effects - Luke Grundy - Aspartate metabolism is an androgen-regulated vulnerability in castration- and enzalutamide-resistant prostate cancer - Jeff Holst - Added value of ctDNA testing with primary treatment for metastatic prostate cancer prognosis - Gert Attard  Sponsored by	0800 – 1030 ANZUP PCFA Nurses & Allied Health Symposium & Clinical Trial Coordinators Session (combined session) E1E2 Co-Chairs: Natasha Roberts, Sally Sara, Brandon Holt and Monika Tencic - Supportive Care Workshop – Haryana Dhillon - Margaret McLennan Oration - Andrea Nixon
1230-1330	Lunch - Foyer E	
1330-1515	ANZUP Masterclass Part One Hall C Co-Chairs: Niara Oliveira and Ed Kwan - Advanced prostate cancer: Alex Mitchell - Renal cancer: Hsiang Tan - Testicular cancer: Jeremy Lewin	
1515-1545	Afternoon tea - Foyer E	
1545-1700	ANZUP Masterclass continues..... Hall C Co-Chairs: Niara Oliveira and Ed Kwan - Bladder cancer: Sophie Plagakis - Early prostate cancer: Braden Higgs	
1700-1830	ANZUP Welcome Reception - Foyer E	
1900 for 1915 to 2200	ANZUP 2026 Evening Symposium The Playford Hotel, North Terrace, Adelaide Chair: Craig Gedye Anna Ma-Wyatt, Natansh Modi & Minh-Son	

MONDAY 29 June 2026

0645-0715	Breakfast will be available in the Trade Hall, Foyer E	
0715-0815	ANZUP sponsored Translational Science Breakfast Translational Rapid-Fire updates Hall C Co-Chairs: Weranja Ranasinghe and Natalie Lister - ADCs in prostate cancer - Shahneen Sandhu - Evolving Immune-Based Treatment Paradigms in Bladder Cancer - Dave Pook - Antibody-Drug Conjugates in Testicular Cancer: Biological Rationale vs Clinical Reality - Nadia Hitchen	Supportive Care Breakfast - Patient centred policy - taking a health economics lens E2&E3 Chair: Natasha Roberts and Juliet de Nittis - Patient Preferences in Cancer Care: Implications for Policy and Practice - Norma Bulamu - Longitudinal qualitative research in clinical trials - Lutfun Hossain - Value Beyond Dollars: A Patient Centred Economic Approach to Policy - Dan Lindsay

	ANZUP Translational subcommittee update – Ed Kwan	Panel Discussion
0830-0900 Hall C	Opening Session Co-Chairs: Lisa Butler and Craig Gedye <i>Sponsored by: Johnson&Johnson</i> - Welcome, Housekeeping and Introduction to ASM - Lisa Butler and Craig Gedye - Welcome to Country – Cliffy Wilson - Welcome from Samantha Oakes, ANZUP CEO and Belinda Jago, ANZUP CAP Member - Welcome by Platinum Sponsor – Steve McCallister, PCFA and Matt Naylor, Johnson & Johnson	
0900-1030 Hall C	Keynote Session One: What Matters Most? When Outcomes Compete <i>When statistically significant gains come at the expense of daily function, quality of life, or cost, how do we decide what truly matters—and who gets to decide? This session explores how these competing priorities are weighed in real-world decision-making, from the patient and multidisciplinary perspectives.</i> Co-Chairs: Craig Gedye and Paul Zawa <i>Sponsored by:  Prostate Cancer Foundation of Australia</i> - CAP introduction – Paul Zawa - Medical oncologist What Matters Most? Saving patients from clinical detriments of relapse after local therapy - Chris Sweeney - Competing Outcomes, Shared Decisions: Who Defines What Matters Most? - Jarad Martin - What Matters Most: Weighing Trade-offs in Urologic Care and Aligning Treatment Decisions with Patient's Priorities - Sarah Psutka - From Costs to Consequences: What Defines Value in Healthcare? - Dan Lindsay - ANZUP Renal subcommittee update - David Pook	
1030-1100	Morning tea - Foyer E	
1100-1230 Hall C	Keynote Session Two: Mind the Gap: Tackling Evidence Uncertainty Across GU Cancers <i>When trials don't have the answer, what do we do? This cross-tumour session examines complementary strategies for advancing care in the face of incomplete evidence — spanning novel preclinical work, biomarker-driven decision-making, consensus guideline development, novel treatment strategies, and real-world data.</i> Co-Chairs: Ed Kwan and Tahlia Scheinberg <i>Sponsored by:  MSD</i> - CAP introduction - Tuan Hoang - Molecular biomarkers for metastatic prostate cancer starting primary treatment - Gert Attard <i>Sponsored by:  BAYER</i> - Bridging the gap between evidence and clinical action - Indranil Mallick - Beyond the Trial Population: The Role of Real-World Evidence in Metastatic Renal Cell Carcinoma - Chun Loo Gan - Discovering New Treatments for Penile Cancer Using Patient-Derived Models - Pauline Mascarinas - Theranostics lab program in PCa - Luc Furic - ANZUP Bladder Urothelial Penile subcommittee update – Dickon Hayne	
1230-1330	Lunch - Foyer E	
1230-1330 E2&E3	Grab lunch and head to E2&E3 for Madame Sapphire's Mystical Guide to Career Success! <i>Sometimes it seems like you need a crystal ball and a fortune teller to try to build a career in medical research – Madame Sapphire will consult The Oracles to help you learn the secrets of their success!</i> Chair: Liz Hovey	
1330-1455 Hall C	Best of the Best Oral Abstracts Session <i>Sponsored by:  astellas</i> [177Lu]Lu-PSMA-617 treatment of high-risk localized prostate cancer selects clones with increased neuro-endocrine differentiation - Paul Neeson	

	- Evaluation of the Plasmalogen Score as a prognostic lipid biomarker in patients with metastatic prostate cancer - Liam Dwyer - Beyond the androgen receptor: decoding master regulators of aggressive prostate cancer - Natalie L. Lister - The methionine aminopeptidase-2 inhibitor, evexomostat, potently suppresses tumour growth in aggressive variant prostate cancer models - Jenni Gunter - A standardised metastatic biopsy platform enabling clinical genomics, patient-derived xenograft generation, and cell-free DNA profiling in metastatic prostate cancer - Sophie Chan - PSMA-PET use in low to favourable intermediate risk prostate cancer patients – a real-world analysis from the statewide INSPIRATION repository - Mrunal Hiwase - The assessment of treatment tolerability through single-item measures: new evidence for EORTC item Q168 - Tamara Jones - The AUSSIE Study: Preliminary Evaluation of Cxbladder Triage Plus for Urothelial Carcinoma Detection in Patients with Haematuria - Weranja Ranasinghe
1455-1525	Afternoon tea - Foyer E – <i>Sponsored by</i> 
1525-1700 Hall C	Keynote Session Three: Supportive Care is Core Business <i>From evidence to practice: an insightful keynote session addressing symptom and side-effect burden through long-term survivorship care</i> Facilitators: Sally Sara and Colin O'Brien <i>Sponsored by:</i>  Prostate Cancer Foundation of Australia - The cancer journey-does it ever end - Colin O'Brien - Supportive oncology - an indispensable component of modern cancer care - Hannah Wardill - Men-Centred Psychological Care after Prostate Cancer - Suzanne Chambers - Moving Medicine: Exercise & Multi-Disciplinary Care as Core Business in Prostate Cancer - Lauren Whiting - Taking a systems level approach to survivorship care - Natasha Roberts - From Surviving to Thriving: Next-Gen Supportive Care to manage symptom and side-effect burden - Survivorship - Sarah Psutka - ANZUP Supportive Care subcommittee update - Natasha Roberts
1700-1730	ANZUP AGM Members only Hall C
1730-1830	Poster Walkaround and pre dinner drinks Foyer E
1900-2300	ANZUP Conference Dinner Panorama Ballroom

TUESDAY 30 June 2026

0715-0815 Hall C	Breakfast Session: The Checkpoint Chaos Circus: Who benefits from cancer immunotherapy? How much? For how long? Chair: Carole Harris <i>Sponsored by</i>  MSD - Belinda Jago - Ganessan Kichenadasse - Louise Nott - Peter Grimison - David Pook Panel Discussion
0830-1000 Hall C	Keynote Session Four: Equity and Access: Expanding who is at the table strengthens outcomes for everyone <i>What are we doing to address structural barriers to participation to ensure inclusion in trials. Everyone wants this and how can we learn from each other.</i>

	Co-Chairs: Natasha Roberts and Raewyn Manssen • CAP introduction - Raewyn Manssen • Equity Challenges of Healthcare for Maori - Andrea Nixon • Inclusion in clinical trial design, bridging demographic and geographic challenges - Indranil Mallick • Exploring population-wide outcomes through data linkage with cancer registries - Kerri Beckman • Towards equity and access to clinical trials for Aboriginal and Torres Strait Islander peoples - Justine Clark • Using the Australian Cancer Plan to improve clinical trial participation - Dorothy Keefe • ANZUP Germ Cell subcommittee update – Ben Tran
1000-1030 Hall C	Plenary Session: Vision to Mission - How are we solving the challenge of delivering clinical trials to everyone? Panel Discussion: Andrea Nixon, Justine Clark, Dorothy Keefe, Peter Grimison, Raewyn Manssen
1030-1100	Morning tea - Foyer E - <i>Sponsored by</i> 
1100-12.50 Hall C	Keynote Session Five: Treatment De/Intensification: Who, When, Why? <i>Intensification of upfront therapy; surrogate endpoints, toxicity trade off vs benefit. De-escalation / intensification of therapy for whom, when and why?</i> Co-Chairs: Laurence Krieger and Braden Higgs <i>Sponsored by: Johnson&Johnson</i> • CAP introduction - Steven Muir-McCarey • Beyond systemic therapy alone: Integrating MDT in the Contemporary management of Oligometastatic prostate cancer - Indranil Mallick • Making Sense of Many Options. Metastatic Hormone Sensitive Prostate Cancer Treatment Selection - Chris Sweeney • An international perspective on including patient-reported outcomes (PROs) in cancer clinical trials - Sandra Nolte • Organoids and Translational Models in Bladder Cancer Identify Therapeutic Approaches - Marianna Kruithof-de Julio • DARO-LIPID: highlight of an ANZUP trial of treatment intensification - Tahlia Scheinberg • ANZADAPT - Laurence Krieger / Craig Gedye • ANZUP Prostate subcommittee update - Lisa Horvath
12.50-1300 Hall C	As trust becomes increasingly important in the age of AI, discover what Australians told us about cancer and information seeking, and be part of the launch of something very special – Samantha Oakes
1300 - 1400	Lunch - Foyer E
1400-1500 Hall C	Plenary Session: The QUEST: Create a clinical trial synopsis for GU cancers <i>As our final session, we aren't just discussing clinical trials: we are building them. By taking all the lessons we've learned during the meeting, we'll work together in 60 minutes. Every one of you will have a clinical trial synopsis ready to bring to the next ANZUP Ideas Generation Workshop</i> Chair: Craig Gedye
1500-1530 Hall C	Plenary Session: ANZUP Awards and #26ANZUPASM close Co-Chairs: Ian Davis, Lisa Butler and Craig Gedye • Summary of The QUEST • ANZUP Awards • Introduction to 2027 / Meet the Convenors for 2027
1530	End of ASM
1545	Coaches depart to the Adelaide Airport